The Wednesday approval of the GSK vaccine, known in development as RSVPreF3 OA, covers the prevention of RSV infection in adults age 60 and older. GSK will market its new product under the brand ...

New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

A vaccine to protect infants in their first six months of life — the age group at highest risk of being hospitalized with RSV — is expected to gain FDA approval later this year.

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The shot, called Arexvy, is the first vaccine cleared by the FDA to protect that population from RSV. The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more ...

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

GSK’s Arexvy received regulatory approval for the prevention of RSV in people 60 and older and is the first RSV vaccine approved for use in the U.S., the FDA said. About the Author Eleanor Laise ...

The FDA has approved the first vaccine fighting a common respiratory virus known as RSV. GSK’s Arexvy shot was cleared for adults 60 years and older.

The U.S. approved the first vaccine for RSV on Wednesday, shots to protect older adults against a respiratory virus that’s most notorious for attacking babies but endangers their grandparents, too.

GSK received the first approval from the Food and Drug Administration for a respiratory syncytial virus (RSV) vaccine, marking a major development in the increasingly competitive RSV space. Arexvy, ...